The Future of Neurological Biomarkers Market

Posted by Sanyukta K on September 15th, 2022

The neurological biomarkers market for Alzheimer's and Parkinson's diseases is studied in US, EU5, Rest of Europe, China, Asia-Pacific and Rest of World (ROW). The US dominated the Alzheimer's and Parkinson's market in 2017 and is expected to continue this trend throughout the forecast period.

A strong increase in neurological biomarkers is expected to increase the incidence of Alzheimer's and Parkinson's diseases. In addition, there has been an increase in the adoption of neurological biomarkers in drug development and validation to improve the accuracy of clinical trials.

Explore Moe Insights@ https://www.alliedmarketresearch.com/request-sample/3555

The Neurological Biomarkers for Alzheimer's Disease market generated a revenue of ,636.7 million in 2017 and is expected to reach ,122.5 million by 2025, registering a CAGR of 11.1% from 2018 to 2025. In contrast, the market for neurological biomarkers will reach ,122.5 million by 2025, and is expected to reach ,457.4 million by 2025, registering a CAGR of 8.0%.

Top Leading Company:

• Abbott Laboratories,
• Myriad RBM,
• Proteome Sciences,
• Thermo Fisher Scientific,
• Athena Diagnostics,
• Immunarray Pvt. Ltd.,
• Quanterix Corporation,
• Diagenic ASA,
• Psynova Neurotech,
• Bio-Rad Laboratories.

Key Benefits:

• Asia-Pacific is expected to register the highest growth rate from 2018 to 2025 in the neurological biomarkers market for Alzheimers.
• The U.S. accounted for maximum revenue in 2017 in the market for both Alzheimers and Parkinsons, and is anticipated to maintain this trend throughout the forecast period.
• EU5 region generated second highest revenue in 2017 in the market for both Alzheimers & Parkinsons, and is expected to continue this trend throughout the forecast period.
• China is estimated to exhibit the highest CAGR of 10.1% from 2018 to 2025 in the neurological biomarkers market for Parkinsons disease.